Alcon Inc. (ALC)
NYSE: ALC · Real-Time Price · USD
75.37
-1.45 (-1.89%)
At close: Oct 7, 2025, 4:00 PM EDT
75.37
0.00 (0.00%)
After-hours: Oct 7, 2025, 6:30 PM EDT
Alcon Revenue
Alcon had revenue of $2.60B in the quarter ending June 30, 2025, with 4.01% growth. This brings the company's revenue in the last twelve months to $10.03B, up 4.04% year-over-year. In the year 2024, Alcon had annual revenue of $9.91B with 4.82% growth.
Revenue (ttm)
$10.03B
Revenue Growth
+4.04%
P/S Ratio
3.75
Revenue / Employee
$391,617
Employees
25,599
Market Cap
37.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.91B | 456.00M | 4.82% |
| Dec 31, 2023 | 9.46B | 738.00M | 8.47% |
| Dec 31, 2022 | 8.72B | 426.00M | 5.14% |
| Dec 31, 2021 | 8.29B | 1.46B | 21.34% |
| Dec 31, 2020 | 6.83B | -675.00M | -8.99% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ALC News
- 7 hours ago - Defender Capital Opposes STAAR Surgical's Proposed Sale to Alcon - PRNewsWire
- 1 day ago - Yunqi Capital, One of STAAR Surgical Company's Largest Shareholders, Reiterates Its Opposition to the Proposed Merger with Alcon - Business Wire
- 1 day ago - Broadwood Partners Issues Letter to STAAR Surgical's Board Questioning Its Judgment in Proposed Sale to Alcon - Business Wire
- 1 day ago - STAAR Surgical: Independent Industry Analysts Recognize Merits of Alcon Merger, the Value It Provides, and the Downside Risks Facing STAAR on Standalone Basis - Business Wire
- 4 days ago - Johnson Fistel Investigates Fairness of Proposed Sale of STAAR Surgical - GlobeNewsWire
- 4 days ago - Broadwood Partners Publishes Presentation Detailing Opposition to STAAR Surgical's Sale to Alcon - Business Wire
- 7 days ago - Alcon and STAAR Surgical Announce Expiration of Hart-Scott-Rodino Waiting Period for Alcon's Acquisition of STAAR - Business Wire
- 8 days ago - Alcon: Seeing Is Believing As Buyout Of STAAR Surgical Hangs In Balance - Seeking Alpha